Literature DB >> 8707738

Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group.

L Verbist1, J Verhaegen, C Wouters, G Vandenhoven.   

Abstract

The comparative activities of piperacillin/tazobactam and other antibiotics against 5625 Gram-negative and Gram-positive bacteria freshly isolated from hospitalized patients was examined. The percentage of Enterobacteriaceae susceptible to piperacillin/tazobactam, ceftazidime, imipenem and ciprofloxacin was very similar and varied from 81% to 84% in the Enterobacteriaceae with inducible type 1 beta-lactamases and from 93 to 97% in the non-inducible organisms. Piperacillin/tazobactam was similar in activity to ceftazidime against Pseudomonas aeruginosa and more active than imipenem or ciprofloxacin. Piperacillin/tazobactam is more active than ceftazidime against Gram-positive bacteria (staphylococci, enterococci) and seems to be a promising antibiotic for nosocomial infections.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707738     DOI: 10.1093/jac/37.2.285

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  2 in total

1.  Mechanism of action and initial evaluation of a membrane active all-D-enantiomer antimicrobial peptidomimetic.

Authors:  Danielle M McGrath; E Magda Barbu; Wouter H P Driessen; Todd M Lasco; Jeffrey J Tarrand; Pablo C Okhuysen; Dimitrios P Kontoyiannis; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-23       Impact factor: 11.205

Review 2.  Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.